Remi Drozd getting us caught up on all that's Happening at Lucid Therapeutics

Duncan Turner MD & Remi Drozd. Lucid Therapeutics’ New Insurance-Covered Ketamine Model, TMS, and the Coming FDA Shift on Psychedelics | Remi Drozd

Remi Drozd returns to the Vagina Doctor podcast to explain how Lucid Therapeutics has evolved after treating thousands of patients, shifting from short, expensive out-of-pocket psychedelic integration to an insurance-covered, co-pay model focused on long-term programs and durability. He describes their patient journey: assessment, trauma- and psychedelic-informed coaching, a workbook-based mindfulness practice, and lower-dose continuous nasal ketamine (often weekly early on, then tapered), with the option to add insurance-covered TMS (36 brief treatments) to further neuromodulate mood pathways. Drozd discusses clinic growth to 10 treatment rooms, expanded staffing, and the operational work required for insurance. He also reviews an FDA hearing on broader psychedelic access, Compass Pathways’ planned psilocybin rollout and monitoring/training considerations, plus adjunct offerings like injectable peptides for sleep and stem cell/MU cell IV therapies that are typically not covered by insurance.

00:00 Remi Drozd getting us caught up on all that's Happening at Lucid Therapeutics

00:30 Welcome Back

00:42 Changes at Lucid Therapeutics

04:44 TMS Treatment Explained

06:57 The Patient Journey

10:40 Practice Expansion

14:31 FDA Psychedelic Hearing

18:26 Compass Pathways & Psilocybin

28:52 Provider Training & Experience

29:57 Stem Cells & Peptides

36:25 Closing & Call to Action